Generex announces commencement of buccal leuprolide R&D work

Publicado por en 8 Sep, 2015 en Noticias | Sin comentarios

Generex Biotechnology Corporation ( today announced that research and development work on buccal leuprolide has begun. The Company previously announced a Memorandum of Understanding with NHTherapeutics, Inc. ( pursuant to which the companies will co-develop a formulation for the delivery of Leuprolide into the human body via the buccal mucosa using the Generex proprietary RapidMist™ buccal drug delivery platform technologies.

Generex has received from NHTherapeutics the first tranche of funding under the Memorandum of Understanding as well as the initial shipment of Leuprolide. The Generex RapidMist™ R&D protocols have been initiated, the goal of which is to achieve a formulation for the safe, simple, rapid, dose-specific, and effective administration of the active pharmaceutical ingredient into the human body via the buccal mucosa, after which local irritation and stability testing will be undertaken.

The companies’ intention is that, upon successful completion of the R&D work, Generex will grant to NHTherapeutics a license for the global commercial exploitation of the product in the field of endocrine disorders in exchange for royalties.

Leuprolide belongs to a class of medications called gonadotropin-releasing hormone (GnRH) agonists.  Traditionally, GnRH agonists are used at a high dose to chronically decrease hormonal release.  Leuprolide is given by injection and is marketed to treat the symptoms associated with advanced prostate cancer, central precocious puberty (CPP), endometriosis, and anemia. NHTherapeutics intends to administer low dose Leuprolide and other GnRH agonists through an easy to use buccal spray to chronically increase hormonal levels.

Other products, such as, insulin, cannabis, … are being developed.

Dejar una Respuesta

Tu dirección de correo electrónico no será publicada.

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

Aviso de cookies